Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimiralisib - PIQUR Therapeutics

Next Previous
Drug Profile

Bimiralisib - PIQUR Therapeutics

Alternative Names: PQR-309

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PIQUR Therapeutics
  • Class Amines; Antineoplastics; Antipsoriatics; Eye disorder therapies; Fluorinated hydrocarbons; Morpholines; Pyridines; Skin disorder therapies; Small molecules; Triazines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Actinic keratosis; Glioblastoma; Head and neck cancer; Lymphoma; Plaque psoriasis
  • Phase I/II Breast cancer
  • No development reported Brain disorders; Eye disorders; Skin cancer; Skin disorders; Solid tumours

Most Recent Events

  • 10 Mar 2025 Efficacy and adverse events data from a phase II trial in Actinic keratosis released by TORQUR
  • 02 Apr 2024 Phase-II clinical trials in Actinic keratosis in Switzerland (Topical) (NCT06319794)
  • 23 Jan 2023 TORQUR acquires Bimiralisib from PIQUR Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top